Contrave vs Wegovy is not a simple “better or worse” choice. Contrave is an oral combination medication that may help with cravings and reward-driven eating, while Wegovy is a once-weekly GLP-1 injection that increases fullness and reduces appetite. The right fit depends on medical history, side-effect risk, treatment preferences, access, and how well each option can be used with nutrition, activity, sleep, and follow-up care.
This comparison focuses on practical decision points. It does not replace a prescribing visit, especially if you have diabetes, depression, seizure risk, pancreatitis history, pregnancy plans, or multiple medications.
Key Takeaways
- Mechanism differs: Contrave targets appetite and reward pathways; Wegovy activates GLP-1 receptors.
- Use differs: Contrave is taken by mouth; Wegovy is injected under the skin weekly.
- Side effects differ: Contrave may cause nausea, headache, insomnia, or mood-related concerns; Wegovy more often causes gastrointestinal symptoms.
- Eligibility matters: Contraindications, drug interactions, pregnancy status, and psychiatric history can change the choice.
- Access can decide: Coverage, supply, cash-pay costs, and pharmacy availability may shape real-world use.
How the Two Medicines Work
Contrave and Wegovy act on different appetite-control systems. Contrave combines naltrexone and bupropion. Naltrexone is an opioid antagonist, meaning it blocks opioid receptors. Bupropion affects norepinephrine and dopamine signaling, which can influence appetite, cravings, and reward-based eating.
Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is an incretin hormone involved in appetite, satiety, and glucose regulation. Semaglutide helps people feel full sooner and may reduce hunger between meals. It also slows stomach emptying, especially earlier in treatment.
Why this matters: two people with the same weight goal may need different support. One person may struggle most with food cravings, while another may describe constant hunger or difficulty feeling full. Those patterns do not determine the prescription by themselves, but they help frame the clinical conversation.
For a deeper look at naltrexone-bupropion, see Contrave for Weight Loss. For semaglutide-focused weight-management context, see Wegovy Weight Loss.
Contrave vs Wegovy: Main Differences at a Glance
The most visible difference is route of use. Contrave is an oral tablet. Wegovy is a subcutaneous injection, meaning it is injected under the skin. That difference affects routines, storage, comfort, and adherence.
| Factor | Contrave | Wegovy |
|---|---|---|
| Active ingredient | Naltrexone plus bupropion | Semaglutide |
| Drug type | Combination appetite and reward-pathway medication | GLP-1 receptor agonist |
| Route | Oral tablet | Weekly injection under the skin |
| Common tolerability issue | Nausea, headache, sleep disturbance | Nausea, vomiting, diarrhea, constipation |
| Key cautions | Seizure risk, blood pressure, mood changes, opioid use | Gallbladder issues, pancreatitis warnings, certain thyroid tumor risk cautions |
| Practical fit | May suit people who prefer tablets and need craving support | May suit people who prefer weekly dosing and need stronger fullness signaling |
Neither option works alone. Prescribers usually pair medication with nutrition planning, physical activity, sleep support, and monitoring. If you are tracking progress, a simple tool can help organize weight change over time without making treatment decisions for you.
Weight-Loss Progress Calculator
Track percentage body-weight change and progress toward a target weight.
These calculations are for education only and do not replace clinical advice, diagnosis, or treatment. Always confirm medical decisions with a qualified healthcare professional.
The calculator estimates weight change and percentage progress toward a goal. It cannot predict medication response or confirm whether a treatment is appropriate.
Effectiveness and Realistic Expectations
Wegovy is often associated with greater average weight reduction in clinical trial settings, but individual response varies. Some people do not tolerate GLP-1 therapy. Others respond well but stop because of gastrointestinal symptoms, access issues, or difficulty maintaining the routine.
Contrave may be useful for people whose eating pattern includes cravings, emotional eating, or reward-driven snacking. It may not be appropriate for people with seizure risk, certain psychiatric concerns, uncontrolled blood pressure, or current opioid use. The medication’s bupropion component also affects how clinicians assess drug interactions and mental health history.
Contrave vs Wegovy should therefore be judged by more than expected weight change. A medication that looks stronger on average may still be the wrong fit if it is not tolerated, accessible, or safe for a specific patient. Likewise, an oral option may be less effective for some people but more sustainable for others.
Quick tip: Bring a brief appetite, craving, sleep, and side-effect log to follow-up visits.
Side Effects, Warnings, and When to Seek Help
Side effects often shape whether people continue therapy. Contrave side effects can include nausea, constipation, headache, dizziness, dry mouth, and insomnia. Some people feel more alert or “wired,” especially during early titration. Others may feel tired as eating habits, sleep, or hydration change.
More serious concerns include mood changes, suicidal thoughts or behavior, increased blood pressure, seizures, severe allergic reactions, and complications related to opioid withdrawal if opioids are used. These issues need clinician review before treatment starts and urgent attention if severe symptoms occur.
Wegovy commonly causes nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These effects may be more noticeable during dose increases. Serious concerns can include pancreatitis symptoms, gallbladder problems, severe dehydration from vomiting or diarrhea, kidney-related complications in some settings, and allergic reactions.
Seek urgent medical care for severe abdominal pain, persistent vomiting, signs of dehydration, chest pain, fainting, swelling of the face or throat, severe mood changes, or suicidal thoughts. Do not stop or restart prescription medication without professional guidance unless emergency instructions apply.
For more detail on early and uncommon reactions, see Contrave Side Effects. For semaglutide titration context, Wegovy Dosage explains how gradual escalation is commonly discussed.
Who May Be a Better Candidate for Each Option?
Clinicians usually start with eligibility, not preference. A person’s diagnosis, medication list, cardiovascular history, psychiatric history, pregnancy status, and prior treatment response all affect the risk-benefit discussion.
When Contrave may fit the discussion
Contrave may enter the conversation when a person prefers an oral medication, has prominent cravings, or cannot access injectable therapy. It may also be considered when GLP-1 therapy is not tolerated or is not available. However, it requires careful review of seizure risk, blood pressure, mood history, eating disorder history, and opioid use.
When Wegovy may fit the discussion
Wegovy may be discussed when a person needs stronger appetite and fullness signaling and can manage weekly injections. It may also be considered when weight-related cardiometabolic risk is part of the care plan. Suitability still depends on contraindications, past pancreatitis or gallbladder concerns, pregnancy considerations, and tolerability.
Some patients compare experiences through contrave reviews or forum posts. Those stories can reveal practical themes, such as nausea, sleep effects, or injection anxiety. They should not replace label information or a clinician’s assessment, because online posts rarely show the full medical picture.
Can They Be Used Together?
Some people ask whether Contrave and Wegovy can be used together. Combination treatment may be considered in select clinical situations, but it requires individualized review. The main concerns are overlapping side effects, tolerability, psychiatric history, blood pressure, medication interactions, and whether the expected benefit justifies added complexity.
Similar questions come up with semaglutide, tirzepatide, Mounjaro, Zepbound, or other GLP-1 and GIP/GLP-1 therapies. In practice, many clinicians prefer changing one variable at a time. That approach makes it easier to identify which medication caused a side effect or benefit.
Do not combine weight-management medications without prescriber direction. This is especially important if you take antidepressants, opioids, seizure-threshold-lowering medicines, diabetes medications, or drugs that affect blood pressure.
Why it matters: Adding therapies can increase uncertainty, even when each medicine is familiar.
How Related Options Compare
Contrave vs Wegovy is only one comparison within obesity care. Other medications may be considered when side effects, access, or treatment response make the first option unsuitable.
Contrave vs phentermine is a common discussion. Phentermine is a sympathomimetic appetite suppressant, meaning it stimulates parts of the nervous system involved in appetite and alertness. That can be helpful for some people, but it can also raise heart rate or blood pressure. Contrave works through different pathways and has different cautions, especially around seizures, mood, and opioid use.
Contrave vs Qsymia compares two combination products. Qsymia contains phentermine and topiramate. It has pregnancy-related restrictions and requires careful counseling because topiramate can cause fetal harm. Contrave has different warnings, including mood-related concerns and seizure risk.
Saxenda vs Wegovy compares two GLP-1 receptor agonists. They differ in active ingredient, administration schedule, and tolerability patterns. If this is your main comparison, see Saxenda vs Wegovy for a more focused injectable-medication review.
Access, Cost, and Product Navigation
Access can be the deciding factor even when the clinical choice seems clear. Insurance coverage, cash-pay affordability, pharmacy supply, prescriber documentation, and jurisdiction rules can all affect continuity. Discuss these issues early, because starting and stopping therapy due to access problems can complicate follow-up.
CanadianInsulin.com is a prescription referral platform. When required, prescription details may be confirmed with the prescriber, while dispensing and fulfilment are handled by licensed third-party pharmacies where permitted. Some patients also explore cash-pay options and cross-border fulfilment depending on eligibility and local rules.
For product-level navigation, review Contrave 8mg/90mg Tablets or Wegovy. For a broader list of related treatments, the Weight Management Products category can help you compare available medication pages without treating them as personal recommendations.
Questions to Ask Before Choosing
A structured discussion can prevent avoidable problems. Bring your medical history, current medications, prior weight-loss treatments, and main concerns to the appointment.
- Safety fit: Which warnings apply to my history?
- Medication interactions: Do my current prescriptions create concerns?
- Side-effect plan: What symptoms should I report early?
- Monitoring needs: Should blood pressure, mood, glucose, or labs be followed?
- Pregnancy plans: Is treatment appropriate now or later?
- Access plan: What happens if supply or coverage changes?
- Stopping rules: When would we pause or switch therapy?
These questions are useful because they turn a brand comparison into a care-plan discussion. They also help avoid choosing a medicine based only on average results or online anecdotes.
Authoritative Sources
Official and regulator-backed references are important for medication indications, boxed warnings, contraindications, and adverse reactions. The FDA approval summary for Wegovy provides regulatory context for semaglutide in chronic weight management.
The FDA approval summary for Contrave outlines key approval context for naltrexone-bupropion. The NIDDK prescription weight-management medication resource gives broader patient-facing background on obesity medicines and safety considerations.
Recap
Contrave targets craving and reward pathways through naltrexone and bupropion. Wegovy works through GLP-1 receptor activation to increase satiety and reduce appetite. Both require medical screening, lifestyle support, and follow-up. The best choice depends on safety, tolerability, preferences, access, and whether the medication can be used consistently.
Contrave vs Wegovy is best approached as a structured discussion with a qualified clinician, not a one-size-fits-all ranking. Ask what risks apply to you, what benefits are realistic, and how progress will be monitored over time.
This content is for informational purposes only and is not a substitute for professional medical advice.
